Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.
Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundqvist M, Walz TM, Aström G, Fujii H, Jacobsson H, Glimelius B. Suzuki C, et al. Among authors: loman n. Med Oncol. 2013 Mar;30(1):415. doi: 10.1007/s12032-012-0415-5. Epub 2013 Jan 16. Med Oncol. 2013. PMID: 23322522 Clinical Trial.
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Hatschek T, et al. Among authors: loman n. Breast Cancer Res Treat. 2012 Feb;131(3):939-47. doi: 10.1007/s10549-011-1880-9. Epub 2011 Nov 18. Breast Cancer Res Treat. 2012. PMID: 22094937 Clinical Trial.
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz TM, Fernö M, Bergh J, Hatschek T. Bjöhle J, et al. Among authors: loman n. Breast Cancer Res Treat. 2013 Jun;139(3):751-8. doi: 10.1007/s10549-013-2579-x. Epub 2013 Jun 5. Breast Cancer Res Treat. 2013. PMID: 23736998 Clinical Trial.
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Tobin NP, et al. Among authors: loman n. Ann Oncol. 2015 Jan;26(1):81-88. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31. Ann Oncol. 2015. PMID: 25361981 Free PMC article. Clinical Trial.
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group. Kimbung S, et al. Among authors: loman n. Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14. Clin Cancer Res. 2016. PMID: 26276891
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group. Kimbung S, et al. Among authors: loman n. Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13. Int J Cancer. 2018. PMID: 28940389 Free PMC article. Clinical Trial.
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T; TEX Trialists Group. Tobin NP, et al. Among authors: loman n. Clin Cancer Res. 2017 Dec 1;23(23):7225-7231. doi: 10.1158/1078-0432.CCR-17-2301. Epub 2017 Sep 29. Clin Cancer Res. 2017. PMID: 28972041 Free PMC article.
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.
Palazon A, Tyrakis PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, Hatschek T, Lövrot J, Foukakis T, Goldrath AW, Bergh J, Johnson RS. Palazon A, et al. Among authors: loman n. Cancer Cell. 2017 Nov 13;32(5):669-683.e5. doi: 10.1016/j.ccell.2017.10.003. Cancer Cell. 2017. PMID: 29136509 Free PMC article.
Immune gene expression and response to chemotherapy in advanced breast cancer.
Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T. Foukakis T, et al. Among authors: loman n. Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25. Br J Cancer. 2018. PMID: 29370583 Free PMC article. Clinical Trial.
296 results